March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Fenofibrate Treatment Could Repress Retinal Adiponectin Expression In Type 1 Diabetes Mellitus Rats
Author Affiliations & Notes
  • Ying-Jung Hsu
    Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan
  • Wei-Shiung Yang
    Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan
  • Chang-Hao Yang
    Ophthalmology, National Taiwan Univ Hospital, Taipei, Taiwan
  • Footnotes
    Commercial Relationships  Ying-Jung Hsu, None; Wei-Shiung Yang, None; Chang-Hao Yang, None
  • Footnotes
    Support  NSC 100-2314-B-002-060-MY3
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2428. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ying-Jung Hsu, Wei-Shiung Yang, Chang-Hao Yang; Fenofibrate Treatment Could Repress Retinal Adiponectin Expression In Type 1 Diabetes Mellitus Rats. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2428.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Adiponectin is a polypeptide hormone exclusively secreted from adipocytes. When it acts with its receptors, adipo R1 and R2, could stimulate AMP-activated protein kinase activity. Studies have showed that serum adiponectin were found to be positively correlated with the severity of diabetic retinopathy. Fenofibrate is a PPAR-α agonist. Recently FIELD and ACCORD eye Study showed that fenofibrate could reduce the risk of microvascular complications and development or progression of diabetic retinopathy. The purpose of this study is to investigate the effect of fenofibrate on the expression of adiponectin and its receptors in retina of rats with type 1 diabetes mellitus.

Methods: : Type 1 diabetes mellitus was induced in Sprague-Dawley rats by intravenous injection of streptozotocin (STZ). Rats were randomly divided into 4 groups : the control group (C), the diabetes group (DM), the diabetes group treated with low-dosage fenofibrate (30 mg/kg/day), and the diabetes group treated with high-dosage fenofibrate (100 mg/kg/day). After 2 months treatment, the expression of adiponectin, adipo R1 and R2 in retina were determined by PCR, western blot and immunofluorescent stain. Aqueous humor and plasma adiponectin were determined by ELISA.

Results: : The expression of mRNA and protein of adiponectin, adipoR1and R2 in the diabetic group were significant higher than the control group. Treatment of fenofibrate dose-dependently suppressed the expression of adiponectin, adipoR1and R2 compared with the non-treatment group. The suppressive effect of fenofibrate on adiponectin expression was confirmed by immunofluorescent stain. Aqueous humor and plasma adiponectin levels also decreased after fenofibrate treatment.

Conclusions: : Treatment of fenofibrate could suppress the expression of adiponectin , adipo R1and R2 in retina of diabetic rats. The beneficial effect of fenofibrate on diabetic retina may be related its regulatory effect on adiponectin and its receptors.

Keywords: diabetic retinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×